A Golden Era of Atopic Dermatitis: New Therapies Address Unmet Needs

Jonathan Silverberg, MD, PhD, MPH


June 29, 2022

While there are still unmet needs in atopic dermatitis, Jonathan Silverberg, MD, PhD, MPH, expresses excitement over the "explosion of development in research of atopic dermatitis" that is currently taking place. Dr Silverberg points to new oral, injectable, and topical therapies that are being approved which have the potential to change the therapeutic landscape for atopic dermatitis.

The oral agents currently undergoing approval will be a first for atopic dermatitis treatment in the United States. Dr Silverberg also addresses the new injectable therapies and nonsteroidal therapies that have excellent long-term efficacy and safety profiles which will give dermatologists additional options to choose from when treating patients, specifically for long-term management of disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.